Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2

Conditions

Melanoma 2Skin Neoplasms 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × bempegaldesleukin × Dermatologic × Clear all
NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
783 enrolled 24 charts
Dermatologic

Melanoma

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated
765 enrolled 13 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡